In the Ad-IL-12/GPC3 group, the tumor inhibition rate was markedly increased (Figure 2F), suggesting Ad-IL-12/GPC3 vaccine could suppress the tumor growth of the subcutaneous tumor models. Here, GPC3 is linked to neoplasm.